Simponi®
Drug class
- Biologic/biosimilar
- TNF blocker
Generic name
Golimumab
Safety
Efficacy
Convenience
Box warning
Golimumab increases the risk of serious infections like tuberculosis, sepsis, and fungal infections. It can also cause cancers like lymphoma, especially in children and teens. Patients should be tested for tuberculosis before starting and watched closely during treatment.
Indications
Approved for moderate to severe ulcerative colitis.
How it works
By inhibiting specific proteins that cause inflammation, biologic medications reduce disease activity and severity.
Drug interactions
TNF-α inhibitors or other immunosuppressants. Do not use live vaccines while you're using this medication.
Pre-treatment screening tests
Viral hepatitis panel, tuberculosis infection, liver function panel, and complete blood count.
Tests during screening
Complete blood count, liver function panel, signs and symptoms of infection, and yearly viral hepatitis panel, tuberculosis infection test, and skin exam.
Payment options
https://www.janssencarepath.com/patient/simponi/cost-supportRoute of administration
Frequency
Every 4 weeks
Side effects
Injection site reactions, signs of common cold, and viral infections.
Contraindications
There are no contraindications listed in the manufacturer's U.S. labeling.
Safety information
Signs of a severe skin reaction, swelling around face.